UK Launches Groundbreaking Trial for Alzheimer's Treatment
A new clinical trial in the UK aims to test diabetes and ADHD medications on Alzheimer's patients to potentially accelerate treatment discovery.
The AD-SMART trial will evaluate the effects of metformin and atomoxetine on Alzheimer's symptoms.
Around 1,200 participants with mild to moderate Alzheimer's will be recruited across the UK.
Results from the trial are expected by 2030, with the possibility of adding more treatments.
A significant clinical trial has commenced in the UK, aiming to expedite the search for effective treatments for Alzheimer's disease. This innovative study, known as AD-SMART, will simultaneously test two repurposed drugs: metformin, typically used for type 2 diabetes, and atomoxetine, prescribed for ADHD. The primary objective is to determine if these medications can alleviate cognitive symptoms and improve the quality of life for individuals affected by Alzheimer's.
Angela Bucksey, a 67-year-old from Cambridgeshire, has become the first participant in this trial after her Alzheimer's diagnosis in January. She expressed her determination to not let the disease define her life, stating that participating in the trial empowers her to take action against the condition. Alzheimer's disease currently affects approximately 600,000 individuals in the UK, making the need for effective treatments urgent.
Prime Minister Andy Burnham, whose father recently passed away due to Alzheimer's, emphasized the importance of this trial in providing cutting-edge treatments to patients. The AD-SMART study employs a multi-arm, multi-stage platform approach, allowing for the simultaneous testing of various treatments while comparing results against a placebo group. This method increases the likelihood of participants receiving active treatments and facilitates quicker adjustments to the trial based on drug efficacy.
The initial focus on metformin and atomoxetine stems from their potential to reduce brain inflammation, a key factor in neurodegeneration, according to chief investigator Prof. Paresh Malhotra. He highlighted the need to accelerate Alzheimer's research, which has historically progressed slowly, often taking years to determine the effectiveness of a single treatment. The trial aims to change this dynamic by leveraging advancements from cancer research to enhance the speed of testing.
The study plans to recruit around 1,200 participants from over 30 locations across the UK, including major cities like London and Edinburgh. Researchers anticipate completing the evaluation of the initial drugs by 2030, with the possibility of introducing additional treatments during the trial. Regular health assessments and cognitive tests will be conducted to monitor the effectiveness of the treatments, providing hope for those affected by this challenging disease.
